Deferred Tax Assets, Operating Loss Carryforwards in USD of Calidi Biotherapeutics, Inc. from Q4 2021 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Calidi Biotherapeutics, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and change rate from Q4 2021 to Q4 2024.
  • Calidi Biotherapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 31 Dec 2024 was $20.2M, a 32.7% increase year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

Calidi Biotherapeutics, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period Value YoY Chg Change % Date Report Filed
Q4 2024 $20.2M +$4.99M +32.7% 31 Dec 2024 10-K 31 Mar 2025
Q4 2023 $15.2M +$5.13M +50.8% 31 Dec 2023 10-K 31 Mar 2025
Q4 2022 $10.1M +$10.1M +25576% 31 Dec 2022 10-K 15 Mar 2024
Q4 2021 $39.3K 31 Dec 2021 10-K 31 Mar 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.